Nebenwirkungen · Sivextro
Sivextro 245 mg powder for oral suspension · Abschnitt 4.8 · PDF-Seite 36
HOS-130299 · Präparat HOS-096879
The following adverse reactions have been identified in two comparative pivotal Phase 3 studies and one post-authorisation study in adults treated with Sivextro (Table 2). Adverse reactions are classified by preferred term and System Organ Class, and by frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥1/10 000 to < 1/1 000); very rare (< 1/10 000); not known (cannot be estimated from the available data).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage 972dc0104b763838069e573cbf38a573bbbce902a883a79962eb814afb84e352 · Zeichen 650–1137 im Abschnitt